Extended-release divalproex in child and adolescent outpatients with epilepsy

Epilepsia

Volumn 46, Issue 3, 2005, Pages 440-443

  Kernitsky, Lydia ^a   O'Hara, Kathryn A ^a   Jiang, Ping ^b   Pellock, John M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Adolescent; Child; Divalproex sodium; Epilepsy; Extended release

Indexed keywords

VALPROATE SEMISODIUM;

ADOLESCENT; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; FEMALE; FEVER; FOLLOW UP; HUMAN; MALE; OTALGIA; OUTPATIENT; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SEIZURE; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADOLESCENT; AGE FACTORS; AMBULATORY CARE; CAPSULES; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 14944357693     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2005.39804.x     Document Type: Article

References (15)

1. Depakote®ER Product Information. North Chicago, IL: Abbott Laboratories, c. 2003.
2. Depakote® Sprinkle Capsules Product Information. North Chicago, IL: Abbott Laboratories, c. 2002.
3. Dutta S, Reed RC. Divalproex to divalproex-ER conversion. Clin Drug Invest (in press).
4. Dutta S, Zhang Y, Conway JM, et al. Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol 2004;30:330-7.
5. Dutta S, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 2002;49:1-10.
6. Centorrino F, Kelleher JP, Berry JM, et al. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. Am J Psychiatry 2003;160:1348-50.
7. Foster RH, Plosker GL. Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics 2000;8:289-306.
8. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 1998;18:52-6.
9. Prisant LM, Bottini B, DiPiro JT, et al. Novel drug delivery systems for hypertension. Am J Med 1992;31(suppl 2A):45S-55S.
10. Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clin Pharm 1991;10:355-8.
11. McCabe PH, Michel NC, McNew CD. Rapid conversion from delayed-release valproic acid to extended-release valproic acid: clinical and pharmacokinetic observations [Abstract 1.284]. In: Program and Abstracts of the 55th annual meeting of the American Epilepsy Society. Philadelphia: December 3, 2001.
12. Thompson NM, Yu K-T T, Mills SM, et al. Safety and efficacy of divalproex sodium extended-release (Depakote ER) in pediatric neurology [Abstract 1.273). In: Program and Abstracts of the 55th annual meeting of the American Epilepsy Society. Philadelphia: December 3, 2001.
13. Thibault M, Blume WT, Saint-Hilaire J-M, et al. Divalproex extended-release versus original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res 2002;50:243-9.
14. Sommerville KS, Dutta S, Biton V, et al. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin Drug Invest 2003;23:661-70.
15. Horne RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol 2003;23:176-81.